| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS30050713 | HIV | ENSG00000115353.11 | protein_coding | TACR1 | No | No | 6869 | P25103 |
| TVIS30050714 | HIV | ENSG00000115353.11 | protein_coding | TACR1 | No | No | 6869 | P25103 |
| TVIS30050715 | HIV | ENSG00000115353.11 | protein_coding | TACR1 | No | No | 6869 | P25103 |
| TVIS30050716 | HIV | ENSG00000115353.11 | protein_coding | TACR1 | No | No | 6869 | P25103 |
| TVIS20001223 | HPV | ENSG00000115353.11 | protein_coding | TACR1 | No | No | 6869 | P25103 |
| TVIS20054272 | HPV | ENSG00000115353.11 | protein_coding | TACR1 | No | No | 6869 | P25103 |
| TVIS20026602 | HPV | ENSG00000115353.11 | protein_coding | TACR1 | No | No | 6869 | P25103 |
| TVIS44004968 | HTLV-1 | ENSG00000115353.11 | protein_coding | TACR1 | No | No | 6869 | P25103 |
| TVIS44011985 | HTLV-1 | ENSG00000115353.11 | protein_coding | TACR1 | No | No | 6869 | P25103 |
| TVIS44011854 | HTLV-1 | ENSG00000115353.11 | protein_coding | TACR1 | No | No | 6869 | P25103 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | TACR1 |
|---|---|
| DrugBank ID | DB00673 |
| Drug Name | Aprepitant |
| Target ID | BE0000384 |
| UniProt ID | P25103 |
| Regulation Type | antagonist |
| PubMed IDs | 11752352; 12590540; 17643344; 12784346; 12227806; 15121485 |
| Citations | Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.@@Brands KM, Payack JF, Rosen JD, Nelson TD, Candelario A, Huffman MA, Zhao MM, Li J, Craig B, Song ZJ, Tschaen DM, Hansen K, Devine PN, Pye PJ, Rossen K, Dormer PG, Reamer RA, Welch CJ, Mathre DJ, Tsou NN, McNamara JM, Reider PJ: Efficient synthesis of NK(1) receptor antagonist aprepitant using a crystallization-induced diastereoselective transformation. J Am Chem Soc. 2003 Feb 26;125(8):2129-35.@@Rodgers J, Bradley B, Kennedy PG: Combination chemotherapy with a substance P receptor antagonist (aprepitant) and melarsoprol in a mouse model of human African trypanosomiasis. Parasitol Int. 2007 Dec;56(4):321-4. Epub 2007 Jun 29.@@Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F: Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer. 2003 Jun 15;97(12):3090-8.@@Zhao MM, McNamara JM, Ho GJ, Emerson KM, Song ZJ, Tschaen DM, Brands KM, Dolling UH, Grabowski EJ, Reider PJ, Cottrell IF, Ashwood MS, Bishop BC: Practical asymmetric synthesis of aprepitant, a potent human NK-1 receptor antagonist, via a stereoselective Lewis acid-catalyzed trans acetalization reaction. J Org Chem. 2002 Sep 20;67(19):6743-7.@@Bergstrom M, Hargreaves RJ, Burns HD, Goldberg MR, Sciberras D, Reines SA, Petty KJ, Ogren M, Antoni G, Langstrom B, Eskola O, Scheinin M, Solin O, Majumdar AK, Constanzer ML, Battisti WP, Bradstreet TE, Gargano C, Hietala J: Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biol Psychiatry. 2004 May 15;55(10):1007-12. |
| Groups | Approved; Investigational |
| Direct Classification | Phenylmorpholines |
| SMILES | C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F |
| Pathways | |
| PharmGKB | PA164747039 |
| ChEMBL | CHEMBL1471 |
